Anosognosia en la enfermedad de Alzheimer: prevalencia, factores asociados e influencia en la evolución de la enfermedad

Sanz, A. Castrillo; Calvo, María Andrés; Gento, I. Repiso; Delgado, E. Izquierdo; Ríos, R. Gutiérrez; Herrero, R. Rodríguez; Sanz, F. Rodríguez; Tola-Arribas, Miguel Ángel

doi:10.1016/j.nrl.2015.03.006

Cited by 17 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Alzheimer's disease (AD), the symptom may be observed in the early stages, even in the mild cognitive impairment stage [14,15]. The incidence ranges from 21% to 38.3% and the prevalence from 24% to 80% and increases as the disease worsens, affecting awareness of memory deficits in parallel with behavioral alterations [16][17][18][19][20]. Among the syndromes of the frontotemporal lobar degeneration (FTLD) spectrum, anosognosia has been reported mainly in the behavioral variant of frontotemporal dementia (bv-FTD) [7,21,22] and targeted specific domains such as personality [21], language, executive functions, and behavioral disturbances [22].…”

Section: Introductionmentioning

confidence: 99%

Anosognosia in Dementia: Evaluation of Perfusion Correlates Using 99mTc-HMPAO SPECT and Automated Brodmann Areas Analysis

et al. 2022

View full text Add to dashboard Cite

(1) Background: Considerable inconsistency exists regarding the neural substrates of anosognosia in dementia in previous neuroimaging studies. The purpose of this study was the evaluation of anosognosia perfusion correlates across various types of dementia using automated Brodmann areas (BAs) analysis and comparison with a database of normal subjects. (2) Methods: We studied 72 patients: 32 with Alzheimer’s disease, 26 with frontotemporal dementia—FTD (12 behavioral FTD, 9 semantic FTD, 5 Progressive Non-Fluent Aphasia), 11 with corticobasal syndrome, and 3 with progressive supranuclear palsy. Addenbrook’s Cognitive Examination—Revised (ACE-R) mean(±SD) was 55.6(±22.8). For anosognosia measurement, the Anosognosia Questionnaire—Dementia was used. Total anosognosia score mean(±SD) was 22.1(±17.9), cognitive anosognosia score mean(±SD) was 18.1(±15.1) and behavioral–mood anosognosia score mean(±SD) was 3.3(±4.7). (3) Results: Higher anosognosia total score was associated with hypoperfusion in the inferior temporal, anterior cingulate, and inferior frontal cortices of the right hemisphere (BAs 20R, 24R, 32R, 45R). Higher anosognosia cognitive score was correlated with hypoperfusion in the left middle and anterior temporal cortices, and right dorsal anterior cingulate cortex (BAs 21L, 22L, 32R). No association was found with behavioral–mood anosognosia. (4) Conclusions: Automated analysis of brain perfusion Single Photon Emission Computed Tomography could be useful for the investigation of anosognosia neural correlates in dementia.

show abstract

Section: Introductionmentioning

confidence: 99%

Anosognosia in Dementia: Evaluation of Perfusion Correlates Using 99mTc-HMPAO SPECT and Automated Brodmann Areas Analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Anosognosia for activities of daily living (ADL) deficits can be present from an early stage of AD dementia and it has a reported frequency between 20 and 80%, and it varies greatly due to the use of diverse diagnostic methods, sampling bias (i.e., community vs. memory clinic samples), and the use of heterogeneous sample sizes [10]. Patients with mild or moderate AD have a reported anosognosia incidence between 21 and 38% and a prevalence between 24.2 and 71.0% [11, 12, 13]. Cross-cultural assessment of the differences in unawareness of memory deficits in a large community-based study has shown regional differences in the frequency of anosognosia (i.e., 81.2% in India, 72.0% in Latin America, and 63.5% in China) [14].…”

Section: Introductionmentioning

confidence: 99%

Clinical Considerations in Physician-Assisted Death for Probable Alzheimer’s Disease: Decision-Making Capacity, Anosognosia, and Suffering

Mondragón

Salame

Kraus

et al. 2019

Dement Geriatr Cogn Disord Extra

View full text Add to dashboard Cite

Background: Requests for physician-assisted death (PAD) in patients with cognitive impairment are complex and require careful consideration. Of particular difficulty is determination of whether the request is voluntary and well considered. Results: Euthanasia and physician-assisted suicide (PAS) are both legal in The Netherlands, Luxemburg, Colombia, and Canada. Euthanasia is legal in Belgium, while PAS is legal in Switzerland and Oregon, Washington, Montana, Vermont, and California (USA). Upon a PAD request, evaluation of the capacity to consent medical treatment is relevant for the decision-making process, while evaluation of testamentary capacity is appropriate before an advance euthanasia directive is written. Anosognosia assessment throughout the Alzheimer’s disease continuum provides essential and relevant information regarding the voluntary and well-considered nature of the PAD request; meanwhile, early assessment of hypernosognosia or subjective cognitive decline assists in formulation of a clinical prognosis. Furthermore, the assessment of physical and psychological suffering should incorporate verbal and nonverbal cues as well as consideration of the psychosocial factors that might affect due care criteria. Conclusion: The clinical approach to a PAD request should consider the legal framework and the decision-making capacity, assess memory deficit awareness and the perception of suffering, and evaluate mental competency when considered pertinent.

show abstract

“…In the context of Alzheimer's disease (AD) anosognosia is considered as one of its symptoms, and its prevalence rate is believed to be between 20% and 81% of diagnosed patients Sanz et al, 2015;Starkstein, 2014). It is observed as being correlated with the severity of the condition (Perrotin et al, 2015;Starkstein, Jorge, Mizrahi, & Robinson, 2006), and it's shown to have a positive correlation with the severity of dementia, age of the patient at symptoms onset and the presence of behavioral disinhibition (Lautenschlager, 2015;Mak, Chin, Ng, Yeo, & Hameed, 2015;Marková, Clare, Wang, Romero, & Kenny, 2005;Mograbi & Morris, 2014).…”

Section: Introductionmentioning

confidence: 99%

Impacto da Anosognosia Associada à Demência de Alzheimer na Qualidade de Vida de Cuidadores

Pereira¹,

Souza²,

Pontes³

et al. 2018

Estud. psicol. (Natal)

View full text Add to dashboard Cite

Alzheimer's disease (AD) has anosognosia as one of its symptoms, defined as a change in the individual's ability to judge their difficulties, and is observed as having a significant impact on quality of life of caregivers. This study evaluated the impact of anosognosia related to AD in quality of life (QoL) of caregivers. Fifty AD patients were evaluated through the Addenbrooke's Cognitive Examination, Dementia Questionnaire-expanded, while caregivers were evaluated using the Scale of QoL in AD and Dementia Questionnaire (caregiver versions). We observed that caregivers of patients with signs of anosognosia had lower scores on QoL and these patients had worse cognitive scores. Anosognosia and QoL were negatively correlated, as QoL and cognitive functioning. Controlling for cognitive functioning, we observed that anosognosia has a greater impact on QoL in individuals with more severe cognitive impairments.

show abstract

Anosognosia en la enfermedad de Alzheimer: prevalencia, factores asociados e influencia en la evolución de la enfermedad

Cited by 17 publications

References 36 publications

Anosognosia in Dementia: Evaluation of Perfusion Correlates Using 99mTc-HMPAO SPECT and Automated Brodmann Areas Analysis

Anosognosia in Dementia: Evaluation of Perfusion Correlates Using 99mTc-HMPAO SPECT and Automated Brodmann Areas Analysis

Clinical Considerations in Physician-Assisted Death for Probable Alzheimer’s Disease: Decision-Making Capacity, Anosognosia, and Suffering

Impacto da Anosognosia Associada à Demência de Alzheimer na Qualidade de Vida de Cuidadores

Contact Info

Product

Resources

About